Psychiatr. pro Praxi, 2006; 2: 84-89

Účinnost a snášenlivost galantaminu v léčbě Alzheimerovy nemoci

doc. MUDr. Vladimír Pidrman Ph.D1, MUDr. Klára Látalová1, Ing. Karel Chroust Ph.D2
1 Psychiatrická klinika FN a LF UP, Olomouc
2 Přírodovědecká fakulta Masarykovy univerzity v Brně

Autoři prezentují roční otevřené sledování účinnosti a snášenlivosti galantaminu v léčbě Alzheimerovy nemoci u ambulantních pacientů. Hodnoceny byly kognitivní funkce, aktivity denního života a výskyt vedlejších účinků. Do sledování bylo zařazeno 27 pacientů (20 žen, 7 mu­žů), 13 pacientů bylo ve věku 74 let a méně, 14 nemocných bylo ve věku vyšším než 74 let. Roční sledování dokončilo 20 nemocných, půlroční sledování všech 27 nemocných. Důvodem vyřazení byla ve všech případech progrese onemocnění spojená s následnou dlouhodobou hospitalizací, nikoliv vedlejší účinky. Autoři dále rozlišují a popisují skupinu respondentů a non-respondentů, vyjadřují se k možnosti predikace účinnosti léčby. Sledování prokázalo dobrou účinnost a snášenlivost v léčbě galantaminem.

Published: April 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pidrman V, Látalová K, Chroust K. Účinnost a snášenlivost galantaminu v léčbě Alzheimerovy nemoci. Psychiatr. praxi. 2006;7(2):84-89.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Auriacombe S, Pere JJ, Loria-Kanza, Vellas B. Efficacy and safety of rivastigmine in patiens with Alzheimer's disease who failed to benefit from treatment with donepezil. Current Medical research and opinion vol. 18, 2002; 3: 129-138. Go to original source... Go to PubMed...
    2. Burns A, Craig S, Lawlor B. Assesment scales in old age psychiatry. Marin Dunitz, London, 1999, 302 p. Go to original source...
    3. Bryant J, Clegg A, Nicholson T et al. Clinical and cost-effectiveness of donepezil, rivastigmin and galantamin for Alzheimer's disease: a rapid and systematic review. Health Technol Assess 2001; 5: 1-137. Go to original source... Go to PubMed...
    4. Cummings, JL The neuropsychiatry of Alzheimer disease and related dementias. London: Martin Dunitz; 2003, p. 312. Go to original source...
    5. Doody RS, Stevens JC, Beck C et al. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154-1166. Go to original source... Go to PubMed...
    6. Gauthier S. Update on diagnostic methods, natural history and outcome variables in Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9 Suppl 3: 2-7. Go to original source... Go to PubMed...
    7. Gauthier S. Alzheimer´s disease. Martin Dunitz, London, 2001, 386 p.
    8. Giacobini E. Cholinesterases and cholinesterase inhibitors. Martin Dunitz, 2000, 270 p.
    9. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. UCP Supplement June 2002; 12: 45-63.
    10. Green, RC. Diagnosis and management of Alzheimer´s didease and other dementias. 2-nd. editon, Professional Communications, Inc., Caddo, 2005, 256 s.
    11. Muller WE, Forstl H. Pharmacological and nonpharmacological approaches to the treatment of dementia. In: Henn, Sartorius, Helmchen, Lauter: Contemporary psychiatry, New York, 2001, vol. 2, pp. 35-46. Go to original source...
    12. Pidrman V, Bouček J. Dlouhodobá léčba demence. Psychiatrie pro praxi 2002; 4: 168-70.
    13. Raskind MA, Peskind ER, Wessel T et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with 6 month extension. The galantamine USA-1 Study Group. Neurology 2000; 54: 2261-2268. Go to original source... Go to PubMed...
    14. Rosler M, Anand R, Cicin-Sain A et el. Efficacy and safety of rivastigmine in patiens with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-638. Go to original source... Go to PubMed...
    15. Reuben BD, Herr KA, Pacala JT et al: Geriatric. Blackwell Publishing, Inc., Malden, 2003, 240 p.
    16. Růžička, E. et al.: Diferenciánlí diagnostika a léčba demencí. Galén, Praha, 2003, 176 p.
    17. Sobotka et al.: Basics in clinical nutrition. Galén, Praha, 2000, 300 p.
    18. Stahl, SM: Essential psychopharmacology. The prescriber´s guide. Cambridge University Press, Cambridge, 2005, 572 p.
    19. Weiner MF, Lipton, AM. Dementias. Diagnossis, treatment and research. 3-rd. Edition, American Psychiatric Publishing, Inc., Washington, 2003, 574 p.
    20. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patiens with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321: 1445-1449. Go to original source... Go to PubMed...
    21. Yudofsky SC, Hales RE. Essentials of neuropsychiatry and clinical neurosciences. American Psychiatric Publishing, Inc., Arlington, 2004, 754 p.
    22. Zurag EG. New treatments of Alzheimer's disease: a review. A Drug Benefit Trends 2001; 13: 27-40.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.